Author

C. Morris

Observed name: Morris, C

OpenAlex ID: A5082397776

OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects

2018 · A.M. Brunt, J. Haviland, et al. · Radiotherapy and Oncology · 16

224 Response to second-line hormonal therapy following progression on bicalutamide (‘casodex’) 150 MG monotherapy

2004 · M. Wirth, P. Iversen, et al. · European Urology Supplements · 9

180 Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Updated analysis at a median 5.4 years' follow-up

2004 · P. Iversen, D. McLeod, et al. · European Urology Supplements · 7

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

2004 · D. McLeod, P. Iversen, et al. · European Urology Supplements · 4

Using the commonsense and transtheoretical models to understand health behaviours after diagnosis with prostate or breast cancer

2011 · Heather Green, Gabriella De Mello Porto Steinnagel, et al. · Griffith Research Online · 3

181 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: Analysis at a median follow-up of 5.4 years

2004 · M. Wirth, P. Iversen, et al. · European Urology Supplements · 2

OC-0610: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results

2020 · A.M. Brunt, J.S. Haviland, et al. · Radiotherapy and Oncology · 1

Works count: 9

Citation count: 43

H-index: 4

I10-index: 1